Bridging the Valley of Death: When MedTech Scale-Ups Should Choose Corporate Capital Over VC

Panel Details & Leadership

Distinguished Panelists

• Gavin Leonard MBA, Chief Executive Officer at MedTech Syndicates, bringing extensive operational expertise in scaling medical device innovations and aligning early-stage syndication with commercial exit strategies.
• Wei Shen, Head of Principal Investment Division at Junson Capital, offering institutional insight into large-scale strategic asset allocation, cross-border investments, and corporate-backed growth models across Asian and global healthcare markets.
• Martin Omid A., Managing Director & Founder at Anthro Ventures, specializing in venture acceleration, deep-tech convergence, and identifying high-value inflection points where strategic corporate alignment accelerates market entry.
• Bibi Sattar Marques, Partner at Buenavista Equity Partners, focusing on private equity execution, healthcare portfolio optimization, and navigating complex capital structures for growth-stage enterprises.

Core Discussion Themes

• The Strategic Tipping Point: Identifying the precise operational and financial metrics that signal a MedTech scale-up is ready to pivot from standard VC funding to corporate-backed investment or strategic M&A integration.
• Navigating CVC Relationships: Weighing the advantages of corporate venture capital—such as accelerated regulatory pathways, supply chain integration, and instant global market credibility—against potential strategic constraints or commercial lock-ins.
• Alternative and Non-Dilutive Funding: Examining innovative capital structures, joint ventures, and non-dilutive financing vehicles that allow founders to fund expensive clinical validation stages while preserving equity control and valuation upside.
• Structuring Win-Win Partnerships: Best practices for negotiating corporate investment terms, defining clear governance boundaries, and protecting intellectual property rights while partnering with industry giants.